RecruitingPhase 4NCT07160504
Vaginal Estrogen Treatment and Effect on Hemostatic Parameters in Postmenopausal Women
Is There an Effect of Local Vaginal Estrogen Treatment on the Hemostatic Parameters in Postmenopausal Women?
Sponsor
University of Aarhus
Enrollment
90 participants
Start Date
Mar 21, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study investigates whether vaginal estrogen treatment has an effect on hemostatic parameters in postmenopausal women. Blood samples are collected before and after 3 months treatment to assess changes in hemostasis.
Eligibility
Sex: FEMALEMin Age: 50 Years
Inclusion Criteria5
- Postmenopausal women aged ≥ 50
- Symptomatic vaginal atrophy
- Indication for standard treatment with vaginal estrogen tablets 10 µg at least three times a week
- Study population 1: without a history of venous thromboembolic event
- Study population 2: with a history of venous thromboembolic event
Exclusion Criteria6
- Unable to give written informed consent
- Does not speak Danish
- Current cancer treatment
- Current treatment with blood thinning medication (except plateletinhibitor)
- Current treatment with local or systematic estrogen
- Systemic inflammatory disease, liver disease or kidney disease
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGVaginal estradiol tablets
Vaginal estrogen tablets 10 µg at least 3 times a week (on indication, prescribed at the outpatient clinic).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07160504